According to VNA correspondent in the UK, on June 1, AstraZeneca updated information on the effectiveness of the breast cancer treatment drug Camizestrant with results that are considered breakthrough.
The information was announced by the British-Swedish pharmaceutical company at the annual conference of the American Society of Clinical Oncology (ASCO) held in Chicago, USA, showing that this drug, which is in the final stage of testing, has proven effective in reducing the risk of tumor growth or death by more than 50% for breast cancer patients.
A global study conducted by AstraZeneca in collaboration with the Institute of Cancer Research in London, the Royal Marsden NHS Foundation Trust and the Curie Institute in Paris (France) showed that patients with advanced breast cancer with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) who used Camizestrant in combination with a CDK4/6 inhibitor had a 56% reduced risk of cancer progression.
In new drug trials, an innovative blood test, called a liquid biopsy or circulating tumor DNA (ctDNA) test, is being used to detect tumor DNA and identify patients at high risk of having mutated tumors before they can be detected on a scan. This test allows patients to be treated with the new drug at an earlier stage.
Also according to information from AstraZeneca, the experimental drug Camizestrant prevents estrogen from attaching to cancer cells and destroys the cell's receptors, making them less resistant to treatments.
The results showed that patients who took the new drug in combination with their current treatment had their disease progression slowed by an average of 16 months, compared with 9.2 months in the group taking the current treatment alone. The trial also found that treatment with the new drug helped patients have a significantly better quality of life for a significantly longer period than the current standard.
In the UK, each year about 55,000 women get breast cancer and 11,500 die, of which about 70% of patients have HR+, HER2- breast cancer.
Experts hope the discovery could open up new treatment strategies for patients with this common type of cancer. The findings from the trial were published simultaneously in the New England Journal of Medicine.
AstraZeneca currently has nine cancer drugs approved for 37 different types and stages of cancer. With the success of the Camizestrant trial, the British-Swedish pharmaceutical group estimates that the new treatment could bring in an additional $5 billion in revenue in its peak year./.
(Vietnam News Agency/Vietnam+)
Source: https://www.vietnamplus.vn/astrazeneca-cong-bo-dot-pha-cua-thuoc-dieu-tri-ung-thu-vu-post1041936.vnp
Comment (0)